Country: Canada
Language: English
Source: Health Canada
FLUTAMIDE
TEVA CANADA LIMITED
L02BB01
FLUTAMIDE
250MG
TABLET
FLUTAMIDE 250MG
ORAL
100/250/500/1000
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0116869001; AHFS:
CANCELLED POST MARKET
2018-04-30
PRODUCT MONOGRAPH Pr TEVA–FLUTAMIDE (flutamide tablets) 250 mg Non-Steroidal Antiandrogen Teva Canada Limited Date of Revision: December 02, 2014 30 Novopharm Court Toronto, Canada M1B 2K9 Control Number: 174585 2 Pr TEVA–FLUTAMIDE (flutamide tablets) THERAPEUTIC CLASSIFICATION Non-Steroidal Antiandrogen ACTION AND CLINICAL PHARMACOLOGY Flutamide demonstrates potent antiandrogenic effects by inhibiting androgen uptake and/or inhibiting nuclear binding of androgen in target tissues. In adult male rats, ventral prostrate weights and seminal vesicle weights were markedly reduced by daily administration of flutamide. PHARMACOKINETICS Analysis of plasma, urine, and feces following a single oral 200 mg dose of tritium-labelled flutamide to human volunteers showed that the drug is rapidly and completely absorbed. It is excreted mainly in the urine with 4.2% of the dose excreted in the faeces over 72 hours. The composition of plasma radioactivity showed that flutamide is rapidly and extensively metabolized, with flutamide comprising 2.5% of plasma radioactivity one hour after administration. At least six metabolites have been identified in plasma. The major plasma metabolite is a biologically active alpha-hydroxylated derivative, which accounts for 23% of the plasma tritium one hour after drug administration. The major urinary metabolite is 2- amino-5-nitro-4-(trifluoromethyl)phenol. Following a single 250 mg oral dose to normal adult volunteers, low plasma levels of varying amounts of flutamide were detected. The biologically active alpha-hydroxylated metabolite reaches maximum plasma levels in about two hours, indicating that it is rapidly formed from flutamide. The plasma half-life for this metabolite is about 6 hours. Following multiple oral dosing of 250 mg three times a day in normal geriatric volunteers, flutamide and its active metabolite approached steady-state plasma levels (based on pharmacokinetic simulations) after the fourth flutamide dose. The half-life of the active metabolite in geriatric volunteers Read the complete document